Results from an expanded phase 1 trial of botensilimab (BOT), a multifunctional anti-CTLA-4, plus balstilimab (BAL; anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer (MSS CRC) Meeting Abstract
| Authors: | Bullock, A.; Fakih, M.; Gordon, M.; Tsimberidou, A.; El-Khoueiry, A.; Wilky, B.; Pimentel, A.; Margolin, K.; Mahadevan, D.; Balmanoukian, A.; Sanborn, R.; Schwartz, G.; Abou-Alfa, G.; Bockorny, B.; Moser, J.; Sharma, S.; Grossman, J.; Rosenthal, K.; O'Day, S.; Lenz, H.; Schlechter, B. |
| Abstract Title: | Results from an expanded phase 1 trial of botensilimab (BOT), a multifunctional anti-CTLA-4, plus balstilimab (BAL; anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer (MSS CRC) |
| Meeting Title: | 25th World Congress on Gastrointestinal Cancer (ESMO 2023) |
| Keywords: | oncology |
| Journal Title: | Annals of Oncology |
| Volume: | 34 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2023 Jun 28-Jul 1 |
| Meeting Location: | Barcelona, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2023-06-01 |
| Start Page: | S178 |
| End Page: | S179 |
| Language: | English |
| ACCESSION: | WOS:001037960400460 |
| DOI: | 10.1016/j.annonc.2023.04.014 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: LBA-4 -- Source: Wos |
